Skip to main
BLTE

BLTE Stock Forecast & Price Target

BLTE Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Belite Bio is a clinical stage biopharmaceutical company focused on developing novel therapies for degenerative retinal diseases and metabolic diseases with unmet medical needs. With a strong pipeline including a product candidate for the treatment of GA and STGD1, as well as a small molecule compound for metabolic diseases, Belite Bio has the potential for significant growth and value creation. The company's recent success in meeting primary endpoints in clinical trials and receiving FDA Breakthrough Therapy Designation for its lead drug candidate further supports a positive outlook for its future success and potential for regulatory approvals. Additionally, its strong financial position with over $750 million in cash and cash equivalents provides a solid foundation for continued research and development efforts.

Bears say

Belite Bio is facing significant risks as a clinical stage biopharmaceutical company, with a negative outlook on its stock due to uncertainties surrounding the success of its product candidate, tinlarebant, in clinical trials and potential regulatory approval. Although the company has presented positive data and completed the NDA submission for tinlarebant, there is no guarantee of FDA approval and commercial success, highlighting the high risk involved in investing in this company. Additionally, the company's current financials are based on projected outcomes and carry a high level of uncertainty, adding to the overall negative outlook on this stock.

BLTE has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Belite Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Belite Bio Inc (BLTE) Forecast

Analysts have given BLTE a Buy based on their latest research and market trends.

According to 6 analysts, BLTE has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $205.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $205.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Belite Bio Inc (BLTE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.